From adaptive design to modern protocol design for drug development: Part I. Editorial and summary of adaptive designs session at the Third FDA/DIA Statistics Forum

Drug Information Journal

Volumn 44, Issue 3, 2010, Pages 325-331

  Wang, Sue Jane ^a   Bretz, Frank ^b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Novartis Pharma AG   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adaptive design paradigm; Clinical scenario planning; Phase 3 development program

Indexed keywords

PLACEBO;

ACCURACY; ANALYTIC METHOD; CASE STUDY; CLINICAL EVALUATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DEVELOPMENT; EFFECT SIZE; EXPLORATORY RESEARCH; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; STATISTICAL ANALYSIS; STUDY DESIGN;

EID: 78249278911     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151004400314     Document Type: Conference Paper

References (13)

1. European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. EMEA CHMP/EWP/2459/02, October 2007.
2. US Food and Drug Administration. Draft guidance for industry: adaptive design clinical trials for drugs and biologics. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegula toryInformation/Guidances/UCM201790. pdf. Released on February 25, 2010, for public comment.
3. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304-1312.
4. Fan F, et al. A novel dose-finding trial in the development of a novel anti-migraine compound. EMEA/EFPIA 2nd Workshop: Adaptive Design in Confirmatory Trials. EMEA Headquarters, UK, 2009. http://www.efpia.eu/content/default.asp ?PageID=559&DocID=6919.
5. Gaydos B. Phase 2/3 adaptive design utilizing a Bayesian decision analytic approach to dose selection. EMEA/EFPIA 2nd Workshop: Adaptive Design in Confirmatory Trials. EMEA Headquarters, UK, 2009. http://www.efpia.eu/content/ default.asp?PageID=559&DocID=6910.
6. US Food and Drug Administration. Guidance for clinical trial sponsors: on the establishment and operation of clinical trial data monitoring committees. March 2006. http://www.fda.gov/down loads/RegulatoryInformation/Guidances/ UCM126578.pdf.
7. International Conference on Harmonization. ICH E4. Dose response information to support drug registration. November 1994. http://www.ich.org/LOB/ media/MEDIA480.pdf.
8. Bornkamp B, Bretz F, Dmitrienko A, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat. 2007;17:965-995.
9. Grieve AP. Discussion of the "white paper of the PhRMA Working Group on Adaptive Dose-Ranging Designs." J Biopharm Stat. 2007;17:997-1004.
10. Wang SJ. Discussion of "white paper of the PhRMA Working Group on Adaptive Dose-Ranging Designs." J Biopharm Stat. 2007;17:1015-1020.
11. Westfall PH, Tsai K, Ogenstad S, Tomoiaga A, Moseley S, Lu Y. Clinical trials simulation: a statistical approach. J Biopharm Stat. 2008;18:611-630.
12. Wang SJ. Commentary on "experiences in model/ simulation for early phase or late phase study planning aimed to learn key design elements." Stat Biopharm Res. 2009;1(4):462-467.
13. US Food and Drug Administration, Health and Human Services. Code of Federal Regulation, 21CFR314.126.